Applications of 211AT and 223RA in targeted alpha-particle radiotherapy

Current Radiopharmaceuticals

Volumn 4, Issue 4, 2011, Pages 283-294

  Vaidyanathan, Ganesan ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha particle radiotherapy; Astatine 211; Radium 223

Indexed keywords

ACTINIUM 225; ALPHARADINA; ASTATINE 211; ASTATOBENZYLGUANIDINE ASTATINE 211; BISMUTH 213; CATION; CHELATING AGENT; DECAY ACCELERATING FACTOR; LIPOSOME; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM 223; TRASTUZUMAB; UNCLASSIFIED DRUG; ASTATINE;

ALPHA RADIATION; BONE METASTASIS; CELL SURVIVAL; CLINICAL TRIAL; DRUG DISTRIBUTION; EXTERNAL BEAM RADIOTHERAPY; HALF LIFE TIME; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; ANIMAL; NEOPLASM; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTATINE; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIUM;

EID: 80052242015     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104040283     Document Type: Review

References (69)

1. Humm, J.L. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med., 1986, 27, 1490-1497.
2. Howell, R.W. Auger processes in the 21st century. Int. J. Radiat. Biol., 2008, 84, 959-975.
3. Boyd, M.; Sorensen, A.; McCluskey, A.G.; Mairs, R.J. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J. Pharm. Pharmacol., 2008, 60, 951-958.
4. 211At]astato-2'- deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res., 1996, 56, 1204-1209.
5. Claesson, A.K.; Stenerlöw, B.; Jacobsson, L.; Elmroth, K. Relative biological effectiveness of the alpha-particle emitter (211)At for double-strand break induction in human fibroblasts. Radiat. Res., 2007, 167, 312-318.
6. Hall, E.J.; Giaccia, A.J. Radiobiology for the Radiologist; Lippincott Williams & Wilkins: Philadelphia, 2006.
7. 131I-labeled monoclonal antibodies? Some dosimetric considerations. Rec. Res. Cancer Res., 1996, 141, 67-75.
8. Vaidyanathan, G.; Zalutsky, M.R. Astatine radiopharmaceuticals: prospects and problems. Curr. Radiopharm., 2008, 1, 177.
9. 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 1335-1344.
10. 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res., 2010, 70, 6815-6823.
11. 211At. Nucl. Med. Biol., 2004, 31, 357-364.
12. 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr. Opin. Investig. Drugs, 2009, 10, 1346-1358.
13. 90Y. Cancer Res., 2009, 69, 8941-8948.
14. Penheiter, A.R; Wegman, T.R; Classic, K.L; Dingli, D.; Bender, C.E; Russell, S.J; Carlson, S.K. Sodium iodide symporter (NIS)- mediated radiovirotherapy for pancreatic cancer. Am. J. Roentgenol., 2010, 195, 341-349.
15. 131I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J. Nucl. Med., 2003, 44, 1827-1838.
16. 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1272-1281.
17. 99mTcpertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl. Med. Biol., 2001, 28, 829-834.
18. 125I uptake-blocking activity in breast cancer. J. Clin. Endocrinol. Metab., 2000, 85, 1245-1250.
19. Li, H.; Peng, K.W.; Dingli, D.; Kratzke, R.A.; Russell, S.J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther., 2010, 17, 550.
20. Trujillo, M.A.; Oneal, M.J.; McDonough, S.; Qin, R.; Morris, J.C. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer Gene Ther., 2010, 17, 1325-1332.
21. 211At on iodide transport and NIS mRNA expression in cultured thyroid cells. J. Nucl. Med., 2009, 50, 1161-1167.
22. 211At alpha-particle irradiation on expression of selected radiation responsive genes in human lymphocytes. Int. J. Radiat. Biol., 2009, 85, 403-412.
23. Turtoi, A.; Sharan, R.N.; Srivastava, A.; Schneeweiss, F.H. Proteomic and genomic modulations induced by γ-irradiation of human blood lymphocytes. Int. J. Radiat. Biol., 2010, 86, 888-904.
24. 211At]MABG J. Label. Compd. Radiopharm., 2007, 50, 177-182.
25. 211At]MABG. Bioorg. Med. Chem., 2007, 15, 3430-3426.
26. 211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug. Chem., 1992, 3, 499-503.
27. 211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl. Med. Biol., 1996, 23, 851-856.
28. Cunningham, S.H.; Mairs, R.J.; Wheldon, T.E.; Welsh, P.C.; Vaidyanathan, G.; Zalutsky, M.R. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br. J. Cancer, 1998, 77, 2061-2068.
29. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res., 1994, 54, 5414-5419.
30. Boyd, M.; Mairs, R.J.; Keith, W.N.; Ross, S.C.; Welsh, P.; Akabani, G.; Owens, J.; Vaidyanathan, G.; Carruthers, R.; Dorrens, J.; Zalutsky, M.R. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J. Gene Med., 2004, 6, 937-947.
31. 211At]meta-astatobenzylguanidine and transfection of the noradrenaline transporter gene Curr. Radiopharm., 2008, 1, 197-202.
32. Boyd, M.; Ross, S.C.; Dorrens, J.; Fullerton, N.E.; Tan, K.W.; Zalutsky, M.R.; Mairs, R.J. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J. Nucl. Med., 2006, 47, 1007-1015.
33. Mairs, R.J., Fullerton, N.E., Zalutsky, M.R., and Boyd, M. Targeted radiotherapy: microgray doses and the bystander effect. Dose-Response, 2007, 5, 204-213.
34. Mairs, R.J.; Boyd, M. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. Nucl. Med. Biol., 2008, 35, 9s-20s.
35. 211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction. Nucl. Med. Biol., 1998, 25, 487-496.
36. 211At-labeled amidobisphophonates. J. Radioanal. Nucl. Chem., 2010, 283, 329-335.
37. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J. Nucl. Med., 1999, 40, 1197-1203.
38. 211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro. Appl. Radiat. Isot., 2010, 68, 1060-1065.
39. Vaidyanathan, G.; Mease, R.C.; Affleck, D.J.; Chen, Y.; Welsh, P.; Hens, M.; Pomper, M.G.; Zalutsky, M.R. An astatine-211 labeled PSMA inhibitor for targeted alpha-particle radiotherapy of prostate carcinoma. J. Nucl. Med., 2009, 50, 11P.
40. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Perry, M.A. Reagents for astatination of biomolecules. 3. Comparison of closodecaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconjug. Chem., 2009, 20, 591-602.
41. 211At. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72, 193-200.
42. Elgqvist, J.; Andersson, H.; Haglund, E.; Jensen, H.; Kahu, H.; Lindegren, S.; Warnhammar, E.; Hultborn, R. Intraperitoneal alpha- radioimmunotherapy in mice using different specific activities. Cancer Biother. Radiopharm., 2009, 24, 509-513.
43. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Vessella, R.L.; Wedge, T.J.; Hawthorne, M.F. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug. Chem., 2007, 18, 1226-1240.
44. Demartis, S.; Tarli, L.; Borsi, L.; Zardi, L.; Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med., 2001, 28, 534-539.
45. Robinson, M.K.; Shaller, C.; Garmestani, K.; Plascjak, P.S.; Hodge, K.M.; Yuan, Q.A.; Marks, J.D.; Waldmann, T.A.; Brechbiel, M.W.; Adams, G.P. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res., 2008, 14, 875-882.
46. 211At labeled HER-2 binding affibody molecules in mice. Oncol. Rep., 2007, 17, 1141-1147.
47. 211At-labeled humanized mono- clonal antibody A33. Cancer Biother. Radiopharm., 2007, 22, 480-487.
48. 211At-MX35 F(ab')2--a phase I study. J. Nucl. Med., 2009, 50, 1153-1160.
49. 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J. Nucl. Med., 2008, 49, 1537-1545.
50. Elgqvist, J.; Andersson, H.; Jensen, H.; Kahu, H.; Lindegren, S.; Warnhammar, E.; Hultborn, R. Repeated intraperitoneal alpharadioimmunotherapy of ovarian cancer in mice. J. Oncol., 2010, 2010, 394913.
51. Elgqvist, J.; Johansson, B. R.; Partheen, K.; Danielsson, A. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity. Anticancer Res., 2010, 30, 2545-2551.
52. 211At-MX35-F(ab')2: a long-term study of renal function in nude mice. Cancer Biother. Radiopharm., 2009, 24, 649-658.
53. 211At-labeled trastuzumab. Nucl. Med. Biol., 2009, 36, 659-669.
54. Nakamae, H.; Wilbur, D.S.; Hamlin, D.K.; Thakar, M.S.; Santos, E.B.; Fisher, D.R.; Kenoyer, A.L.; Pagel, J.M.; Press, O.W.; Storb, R.; Sandmaier, B.M. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res., 2009, 69, 2408-2415.
55. 211At]astatine. Bioconjug. Chem., 2009, 20, 1983-1991.
56. 211At-labeled and biotinylated poly-Llysine as effector molecule. Cancer, 2010, 116, 1101-1110.
57. 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 851-861.
58. Mazeron, J.J.; Gerbaulet, A. The centenary of discovery of radium. Radiother. Oncol., 1998, 49, 205-216.
59. Bruland, O.S.; Jonasdottir, T.; Fisher, D.R.; Larsen, R.H. Radium-223: From radiochemical development to clinical applications in targeted cancer therapy. Curr. Radiopharm., 2008, 1, 203-208.
60. Dutreix, J.; Tubiana, M.; Pierquin, B. The hazy dawn of brachytherapy. Radiother. Oncol., 1998, 49, 223-232.
61. 89Sr in mice. J. Nucl. Med., 2003, 44, 252-259.
62. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res., 2002, 62, 3120-3125.
63. 223Ra injected intravenously into mice: histology, clinical chemistry and hematology. In vivo, 2006, 20, 325-331.
64. 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res., 2006, 12, 6250s-6257s.
65. Nilsson, S.; Larsen, R.H.; Fossa, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.E.; Salberg, G.; Bruland, O.S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res., 2005, 11, 4451-4459.
66. Nilsson, S.; Franzen, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernas, B.; Petersson, U.; Johannessen, D.C.; Sokal, M.; Pigott, K.; Yachnin, J.; Garkavij, M.; Strang, P.; Harmenberg, J.; Bolstad, B.; Bruland, O.S. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol., 2007, 8, 587-594.
67. Henriksen, G.; Hoff, P.; Larsen, R.H. Evaluation of potential chelating agents for radium. Appl. Radiat. Isot., 2002, 56, 667-671.
68. Henriksen, G.; Schoultz, B.W.; Michaelsen, T.E.; Bruland, O.S.; Larsen, R.H. Sterically stabilized liposomes as a carrier for alphaemitting radium and actinium radionuclides. Nucl. Med. Biol., 2004, 31, 441-449.
69. 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res., 2006, 26, 2841-2848.